[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613595":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":174,"collaborators":25,"id":176,"slug":25,"hasResults":177,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":25,"eligibilityCriteria":181,"healthyVolunteers":177,"sex":182,"minAge":183,"maxAge":25,"enrollmentInfo":184,"targetDuration":25,"studyType":187,"phases":188,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},{"fullName":5,"class":6},"Akebia Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Praliciguat","EXPERIMENTAL","Praliciguat will be administered daily with dose escalation to a target dose during a 24-week double-blind period, followed by a 24-week open-label treatment period.",[13],"Drug: Praliciguat",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matching placebo will be administered daily for 24 weeks",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Oral Tablet",[9],null,{"type":27,"name":15,"description":23,"armGroupLabels":28,"otherNames":25},"OTHER",[15],[30],{"name":5,"role":31,"phone":32,"phoneExt":25,"email":33},"CONTACT","16178446128","trials@akebia.com",[35,48,57,66,76,86,95,104,114,125,135,145,155,165],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":25},"Investigator Site #2","RECRUITING","Chula Vista","California","91910","United States",{"type":43,"coordinates":44},"Point",[45,46],-117.0842,32.64005,{"lat":46,"lon":45},{"facility":49,"status":37,"city":50,"state":39,"zip":51,"country":41,"cosmosGeoPoint":52,"geoPoint":56,"contacts":25},"Investigator Site #14","Los Angeles","90022",{"type":43,"coordinates":53},[54,55],-118.24368,34.05223,{"lat":55,"lon":54},{"facility":58,"status":37,"city":59,"state":39,"zip":60,"country":41,"cosmosGeoPoint":61,"geoPoint":65,"contacts":25},"Investigator Site #12","San Dimas","91773",{"type":43,"coordinates":62},[63,64],-117.80673,34.10668,{"lat":64,"lon":63},{"facility":67,"status":37,"city":68,"state":69,"zip":70,"country":41,"cosmosGeoPoint":71,"geoPoint":75,"contacts":25},"Investigator Site #13","Arvada","Colorado","80002",{"type":43,"coordinates":72},[73,74],-105.08748,39.80276,{"lat":74,"lon":73},{"facility":77,"status":37,"city":78,"state":79,"zip":80,"country":41,"cosmosGeoPoint":81,"geoPoint":85,"contacts":25},"Investigator Site #6","Coral Springs","Florida","33071",{"type":43,"coordinates":82},[83,84],-80.2706,26.27119,{"lat":84,"lon":83},{"facility":87,"status":37,"city":88,"state":79,"zip":89,"country":41,"cosmosGeoPoint":90,"geoPoint":94,"contacts":25},"Investigator Site #7","Miami","33172",{"type":43,"coordinates":91},[92,93],-80.19366,25.77427,{"lat":93,"lon":92},{"facility":96,"status":37,"city":97,"state":79,"zip":98,"country":41,"cosmosGeoPoint":99,"geoPoint":103,"contacts":25},"Investigator Site #8","Orlando","32806",{"type":43,"coordinates":100},[101,102],-81.37924,28.53834,{"lat":102,"lon":101},{"facility":105,"status":37,"city":106,"state":107,"zip":108,"country":41,"cosmosGeoPoint":109,"geoPoint":113,"contacts":25},"Investigator Site # 1","Lawrenceville","Georgia","30046",{"type":43,"coordinates":110},[111,112],-83.98796,33.95621,{"lat":112,"lon":111},{"facility":115,"status":116,"city":117,"state":118,"zip":119,"country":41,"cosmosGeoPoint":120,"geoPoint":124,"contacts":25},"Investigator Site #3","TERMINATED","Chicago","Illinois","60643",{"type":43,"coordinates":121},[122,123],-87.65005,41.85003,{"lat":123,"lon":122},{"facility":126,"status":37,"city":127,"state":128,"zip":129,"country":41,"cosmosGeoPoint":130,"geoPoint":134,"contacts":25},"Investigator Site #11","Louisville","Kentucky","40205",{"type":43,"coordinates":131},[132,133],-85.75941,38.25424,{"lat":133,"lon":132},{"facility":136,"status":37,"city":137,"state":138,"zip":139,"country":41,"cosmosGeoPoint":140,"geoPoint":144,"contacts":25},"Investigator Site #10","Pontiac","Michigan","48341",{"type":43,"coordinates":141},[142,143],-83.29105,42.63892,{"lat":143,"lon":142},{"facility":146,"status":37,"city":147,"state":148,"zip":149,"country":41,"cosmosGeoPoint":150,"geoPoint":154,"contacts":25},"Investigator Site #4","Chattanooga","Tennessee","37404",{"type":43,"coordinates":151},[152,153],-85.30968,35.04563,{"lat":153,"lon":152},{"facility":156,"status":37,"city":157,"state":158,"zip":159,"country":41,"cosmosGeoPoint":160,"geoPoint":164,"contacts":25},"Investigator Site #5","Arlington","Texas","76015",{"type":43,"coordinates":161},[162,163],-97.10807,32.73569,{"lat":163,"lon":162},{"facility":166,"status":37,"city":167,"state":158,"zip":168,"country":41,"cosmosGeoPoint":169,"geoPoint":173,"contacts":25},"Investigator Site #9","Dallas","75231",{"type":43,"coordinates":170},[171,172],-96.80667,32.78306,{"lat":172,"lon":171},{"type":175,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100613595",false,"NCT07268638","A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis","Inclusion Criteria:\n\n1. UPCR ≥1 (g\u002Fg) during screening.\n2. On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent.\n3. Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n4. Kidney biopsy within 3 years of screening consistent with FSGS or documentation of a genetic mutation in a podocyte protein associated with FSGS.\n\nExclusion Criteria:\n\n1. Collapsing FSGS in the kidney biopsy report.\n2. Sickle cell disease.\n3. HbA1c \\>8% or non-fasting blood glucose \\>180 milligram\u002Fdecilitre.\n4. Uncontrolled hypertension (≥160\u002F100 millimeters of mercury)","ALL","18 Years",{"count":185,"type":186},60,"ESTIMATED","INTERVENTIONAL",[189],"PHASE2","This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.",[192],"Focal Segmental Glomerulosclerosis",[194,195,196,197],"Glomerular Disease","Chronic Kidney Disease","Proteinuria","Urine protein-to-creatinine ratio","2026-06-03",{"date":200,"type":201},"2026-06-05","ACTUAL",{"date":203,"type":201},"2025-12-03",{"date":205,"type":186},"2028-01",{"name":5,"class":6},14]